NEU 3.50% $14.05 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1331

  1. 1,239 Posts.
    lightbulb Created with Sketch. 317
    agree if NEU is following through phase 3 and subsequently decides to do a licensing deal (which is unlikely in my view), the terms would be substantially better than Acadia's. The company quoted $50-$100m AUD not USD for a phase 3 trail which is comparable to what E&P estimated at USD $40m (they simply use the mid point)
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.